Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 634 | 121 | 504 |
| Samples | 591 | 112 | 471 |
| Peptides | 450 | 80 | 384 |
Function
PDGFRB · Platelet derived growth factor receptor beta
The protein encoded by this gene is a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. These growth factors are mitogens for cells of mesenchymal origin. The identity of the growth factor bound to a receptor monomer determines whether the functional receptor is a homodimer (PDGFB or PDGFD) or a heterodimer (PDGFA and PDGFB). This gene is essential for normal development of the cardiovascular system and aids in rearrangement of the actin cytoskeleton. This gene is flanked on chromosome 5 by the genes for granulocyte-macrophage colony-stimulating factor and macrophage-colony stimulating factor receptor; all three genes may be implicated in the 5-q syndrome. A translocation between chromosomes 5 and 12, that fuses this gene to that of the ETV6 gene, results in chronic myeloproliferative disorder with eosinophilia. [provided by RefSeq, Aug 2017].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000261799 | P09619 | 634 | 450 |
Gene Properties
Recurrent Mutations
All 450 amino-acid changes on canonical ENST00000261799 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PDGFRB · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PDGFRB – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 6/40 15% | 0/0 0% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| Endometrial Carcinoma | 5/42 12% | 21/612 3% |
| Melanoma | 10/210 5% | 71/1899 4% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Other Solid Cancers | 3/94 3% | 42/1515 3% |
| Non-Small Cell Lung Carcinoma | 13/304 4% | 29/1390 2% |
| Squamous Cell Lung Carcinoma | 7/57 12% | 14/810 2% |
| Gastric Carcinoma | 1/74 1% | 42/1809 2% |
| Small Cell Lung Carcinoma | 0/9 0% | 15/752 2% |
| Osteosarcoma | 0/45 0% | 4/166 2% |
| Colorectal Carcinoma | 11/143 8% | 52/3239 2% |
| Other Sarcomas | 6/69 9% | 7/699 1% |
| Bladder Carcinoma | 1/58 2% | 16/956 2% |
| Neuroendocrine Tumour | 9/154 6% | 2/577 0% |
| Cervical Carcinoma | 0/35 0% | 5/422 1% |
| Non-Cancerous | 3/104 3% | 7/830 1% |
| Biliary Tract Carcinoma | 4/54 7% | 6/950 1% |
| Ovarian Carcinoma | 2/109 2% | 9/998 1% |
| Head and Neck Carcinoma | 0/85 0% | 16/1574 1% |
| Ewings Sarcoma | 0/63 0% | 3/262 1% |
| Mesothelioma | 1/62 2% | 1/165 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Hepatocellular Carcinoma | 1/46 2% | 16/2210 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Glioma | 0/52 0% | 14/2127 1% |
| Prostate Carcinoma | 2/13 15% | 10/2105 0% |
| Thyroid Gland Carcinoma | 1/45 2% | 8/1592 0% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 13/2550 1% |
Mutation Distribution
Where PDGFRB is mutated · all tissues, split by cell line vs tissue
How many mutations in PDGFRB were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 634 mutations in PDGFRB
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|